XML 52 R40.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Acquisitions - Narrative (Details) shares in Thousands, $ in Thousands |  |  |  |  |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 9 Months Ended | 12 Months Ended
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
May 23, 2018 USD ($) | May 18, 2018 USD ($) | Apr. 06, 2018 USD ($) | Feb. 14, 2018 USD ($) | Oct. 02, 2017 USD ($) | Aug. 04, 2017 USD ($) | Jul. 03, 2017 USD ($) | May 01, 2017 USD ($) | Jan. 31, 2017 USD ($) patents | Jul. 31, 2018 USD ($) shares | Sep. 30, 2018 USD ($) | Sep. 30, 2018 USD ($) | Sep. 30, 2017 USD ($) | Dec. 31, 2017 USD ($)
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire intangible assets |  |  |  |  |  |  |  |  |  |  |  | $ 2,234 | $ 1,927 |
Loan for long-term agreement |  |  |  |  |  |  |  |  |  |  |  | 10,750 | $ 0 |
QX Medical, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments to acquire intangible assets |  | $ 750 |  |  |  |  |  |  |  |  |  |  |  |
NinePoint |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option to purchase outstanding equity, up to |  |  | 100.00% |  |  |  |  |  |  |  |  |  |  |
Consideration received, option to purchase remaining equity |  |  | $ 10,000 |  |  |  |  |  |  |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  | $ 1,400 | $ 2,500 |  |
Loan for long-term agreement |  |  | $ 10,500 |  |  |  |  |  |  |  |  |  |  |
Interest rate on loan |  |  | 9.00% |  |  |  |  |  |  |  |  |  |  |
Distribution agreements | QX Medical, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  | 10 years |  |  |  |  |  |  |  |  |  |  |  |
DirectACCESS Medical, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price | $ 7,300 |  |  |  |  |  |  |  |  |  |  |  |  |
Weighted average useful life | 9 years 10 months 24 days |  |  |  |  |  |  |  |  |  |  |  |  |
DirectACCESS Medical, LLC | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |
DirectACCESS Medical, LLC | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life | 10 years |  |  |  |  |  |  |  |  |  |  |  |  |
DirectACCESS Medical, LLC | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life | 5 years |  |  |  |  |  |  |  |  |  |  |  |  |
Becton, Dickinson and Company |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  | $ 100,300 |  |  |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  |  |  |  | 8 years |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  | 11,800 | $ 30,300 |  |
Acquisition-related costs |  |  |  |  |  |  |  |  |  |  |  | $ 1,800 |  |
Becton, Dickinson and Company | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  |  |  |  | 8 years |  |
Becton, Dickinson and Company | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  |  |  |  | 9 years |  |
Becton, Dickinson and Company | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  |  |  |  | 7 years |  |
ITL Healthcare Pty Ltd |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  | $ 11,300 |  |  |  |  |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  | 1,900 | $ 6,100 |  |
ITL Healthcare Pty Ltd | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  | 7 years |  |  |  |  |  |  |  |  |
Laurane Medical S.A.S. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  | $ 16,500 |  |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  | 11 years 10 months 24 days |  |  |  |  |  |  |  |
Contingent liability |  |  |  |  |  | $ 5,500 |  |  |  |  |  |  |  |
Laurane Medical S.A.S. | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  | 12 years |  |  |  |  |  |  |  |
Laurane Medical S.A.S. | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  | 1 year |  |  |  |  |  |  |  |
Osseon LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  | $ 6,800 |  |  |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  | 9 years |  |  |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  | 478 | 1,600 |  |
Osseon LLC | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  | 9 years |  |  |  |  |  |  |
Osseon LLC | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  | 8 years |  |  |  |  |  |  |
Vascular Access Technologies, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  | $ 5,000 |  |  |  |  |  |
Contingent liability |  |  |  |  |  |  |  | $ 4,900 |  |  |  |  |  |
Vascular Access Technologies, Inc. | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  | 15 years |  |  |  |  |  |
Argon Medical Devices, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  |  | $ 10,100 |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  | 6 years |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  | 11,000 | 34,200 |  |
Initial payment, before working capital adjustment |  |  |  |  |  |  |  |  | $ 10,900 |  |  |  |  |
Working capital adjustment |  |  |  |  |  |  |  |  | $ (797) |  |  |  |  |
Argon Medical Devices, Inc. | Cardiovascular Segment |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition-related costs |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,600
Argon Medical Devices, Inc. | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  | 7 years |  |  |  |  |
Argon Medical Devices, Inc. | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |
Argon Medical Devices, Inc. | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |
Catheter Connections, Inc. |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total purchase price |  |  |  |  |  |  |  |  | $ 38,000 |  |  |  |  |
Weighted average useful life |  |  |  |  |  |  |  |  | 11 years 8 months 12 days |  |  |  |  |
Net sales related to acquisition |  |  |  |  |  |  |  |  |  |  | $ 3,700 | $ 10,100 |  |
Number of patents acquired | patents |  |  |  |  |  |  |  |  | 40 |  |  |  |  |
Catheter Connections, Inc. | Cardiovascular Segment |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Acquisition-related costs |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 482
Catheter Connections, Inc. | Developed technology |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  | 12 years |  |  |  |  |
Catheter Connections, Inc. | Trademarks |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  | 10 years |  |  |  |  |
Catheter Connections, Inc. | Customer Lists |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Useful life |  |  |  |  |  |  |  |  | 8 years |  |  |  |  |
Cagent Vacsular, LLC |  |  |  |  |  |  |  |  |  |  |  |  |  |
Business Acquisition [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |
Preferred limited liability company units (in units) | shares |  |  |  |  |  |  |  |  |  | 1,786 |  |  |  |
Payments to purchase preferred limited liability company units |  |  |  |  |  |  |  |  |  | $ 2,200 |  |  |  |
Equity method investment, ownership percentage |  |  |  |  |  |  |  |  |  | 19.50% |  |  |  |

X
- Definition Business Acquisition, Consideration Received, Option to Purchase Remaining Equity + References No definition available. + Details
Name: | mmsi_BusinessAcquisitionConsiderationReceivedOptionToPurchaseRemainingEquity
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Business Acquisition, Option to Acquire Percentage of Voting Interests + References No definition available. + Details
Name: | mmsi_BusinessAcquisitionOptionToAcquirePercentageOfVotingInterests
Namespace Prefix: | mmsi_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Business Combination, Consideration Transferred, Amount Prior to Price Adjustment + References No definition available. + Details
Name: | mmsi_BusinessCombinationConsiderationTransferredAmountPriorToPriceAdjustment
Namespace Prefix: | mmsi_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Equity Method Investment, Limited Liability Company (LLC) Units + References No definition available. + Details
Name: | mmsi_EquityMethodInvestmentLimitedLiabilityCompanyLLCUnits
Namespace Prefix: | mmsi_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Notes Receivable, Interest Rate, Stated Percentage + References No definition available. + Details
Name: | mmsi_NotesReceivableInterestRateStatedPercentage
Namespace Prefix: | mmsi_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of Patents Acquired + References No definition available. + Details
Name: | mmsi_NumberOfPatentsAcquired
Namespace Prefix: | mmsi_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (a)(3) -URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275 + Details
Name: | us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_BusinessAcquisitionLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 25 -Paragraph 23 -URI http://asc.fasb.org/extlink&oid=84229725&loc=d3e1043-128460 + Details
Name: | us-gaap_BusinessCombinationAcquisitionRelatedCosts
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 8 -URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6613-128477 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 30 -Paragraph 7 -URI http://asc.fasb.org/extlink&oid=109124213&loc=d3e6578-128477 + Details
Name: | us-gaap_BusinessCombinationConsiderationTransferred1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of liability recognized arising from contingent consideration in a business combination. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 50 -Paragraph 1 -Subparagraph (c)(1) -URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 35 -Paragraph 1 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=6911338&loc=d3e6819-128478 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -URI http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476 + Details
Name: | us-gaap_BusinessCombinationContingentConsiderationLiability
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition This element represents the amount of revenue of the acquiree since the acquisition date included in the consolidated income statement for the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -URI http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463 + Details
Name: | us-gaap_BusinessCombinationProFormaInformationRevenueOfAcquireeSinceAcquisitionDateActual
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to items of consideration transferred in connection with a business combination for which the initial accounting was incomplete. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -SubTopic 20 -Section 50 -Paragraph 4A -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=84161108&loc=SL65897772-128472 + Details
Name: | us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentConsiderationTransferred
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (a)(1) -URI http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 + Details
Name: | us-gaap_EquityMethodInvestmentOwnershipPercentage
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireEquityMethodInvestments
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash outflow to acquire an agreement for an unconditional promise by the maker to pay the entity (holder) a definite sum of money at a future date. Such amount may include accrued interest receivable in accordance with the terms of the note. The note also may contain provisions including a discount or premium, payable on demand, secured, or unsecured, interest bearing or noninterest bearing, among myriad other features and characteristics. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 13 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=109223946&loc=d3e3213-108585 + Details
Name: | us-gaap_PaymentsToAcquireNotesReceivable
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=mmsi_QXMedicalLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=mmsi_NinePointMedicalInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_DirectACCESSMedicalLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerListsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_BectonDickinsonandCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_ITLHealthcarePtyLtdMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_LauraneMedicalS.A.S.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_OsseonLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_VascularAccessTechnologiesInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_ArgonMedicalDevicesInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mmsi_CardiovascularSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=mmsi_CatheterConnectionsInc.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=mmsi_CagentVacsularLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |